Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zonagen IncfiledCriticalZonagen Inc
Priority to ARP020104443priorityCriticalpatent/AR037563A1/en
Publication of AR037563A1publicationCriticalpatent/AR037563A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Plant Substances
(AREA)
Abstract
Composiciones de fármacos mejorados y métodos útiles en el tratamiento de la disfunción eréctil masculina. Una mezcla optimizada de los fármacos mesilato de fentolamina, clorhidrato de papaverina, y alprostadilo, en un amortiguador que contiene L-arginina y glicina, se inyecta en el tejido del pene para producir una erección en hombres que en otras circunstancias son impotentesImproved drug compositions and methods useful in the treatment of male erectile dysfunction. An optimized mixture of the drugs phentolamine mesylate, papaverine hydrochloride, and alprostadil, in a buffer containing L-arginine and glycine, is injected into the penile tissue to produce an erection in men who are otherwise impotent.
ARP0201044432002-11-192002-11-19
IMPROVED COMPOSITIONS FOR THE TREATMENT OF MALE ERECTILE DYSFUNCTION
AR037563A1
(en)
method for preparing an opioid antagonist-containing composition, opioid antagonist-containing product, opioid antagonist-containing composition, injectable dosage formulation, kit, method for preventing or treating an opioid-associated side effect in a patient, and for treating or preventing pain in a patient
Intracavernous, Transurethral, and Topical Therapies for Erectile Dysfunction in the Era of Oral Pharmacotherapy: Salvaging First-Line Therapy Failures With Combination Therapies